Evidence map›Paper›PMID 27639252›Full record

ArticleHepatology (Baltimore, Md.)2016

Hepatitis B virus X protein crosses out Smc5/6 complex to maintain covalently closed circular DNA transcription.

Bidisha Mitra, Haitao Guo

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Identification ofFrontiers in immunology · 2018
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Recent Advances in Hepatitis B Treatment.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bidisha MitraDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN.
Haitao GuoDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN.

Funding

Molecular Mechanisms of HBV cccDNA FormationR01AI110762 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2016 to 2025
$3.5M
Development of a novel drug candidate that inhibits hepatitis B virus covalentlyR01AI094474 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI GUO, HAITAO · 2011 to 2015
$3.4M
Development of an HTS Assay for Discovery of HBV cccDNA InhibitorsR01AI123271 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2017 to 2019
$1.2M
Molecular Mechanisms of ZAP/ISG20 mediated HBV RNA DecayR21AI103838 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI GUO, HAITAO · 2014 to 2015
$429k
NIAID NIH HHS R01 AI094474NIAID NIH HHS R01 AI110762NIAID NIH HHS R01 AI123271NIAID NIH HHS R21 AI103838
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Host-Pathogen InteractionsTranscription, GeneticCell Cycle ProteinsChromosomal Proteins, Non-HistoneDNA, CircularHumansTrans-ActivatorsViral Regulatory and Accessory ProteinsVirus ReplicationCell Cycle ProteinsChromosomal Proteins, Non-HistoneDNA, Circularhepatitis B virus X proteinSMC5 protein, humanSMC6 protein, humanTrans-ActivatorsViral Regulatory and Accessory Proteins

Identifiers

PMID27639252
PMCPMC5115954

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.